Over the past 15 years, with the introduction of increasingly intensive protocols, the nature of paediatric oncology has changed significantly. This has been accompanied by improved survival figures for children with both haematological and solid malignancies. It An understanding of the benefits of an intensive care unit is therefore important for decision making and for counselling of the families involved. It was for these reasons that we undertook the present study.
Patients and methods This study was performed over a six and a half year period, from July 1984 to December 1990. Details were recorded of all patients from the paediatric oncology unit at St James's University Hospital, Leeds, who required admission to the intensive care unit (ICU). The information used in this study was collected contemporaneously by the ICU, and was then clarified by retrospective chart review. There were a total of 65 patients admitted on 70 occasions in the study. Their underlying oncological diagnoses are given in table 1. Their mean age was 6-6 years (range 2 months-14-5 years), and there were 39 boys and 26 girls.
The paediatric oncology unit is a regional unit, serving Yorkshire and Humberside. There are on average 100 new patients presenting with primary malignancies each year. The only patients not included in this study were those requiring specialised neurosurgery, who were operated on at two nearby, regional neurology centres. However, many received subsequent medical treatment at St James's University Hospital.
The ICU is a combined adult and paediatric unit. Admission to the ICU is restricted by bed availability, and our oncology ward is capable of functioning as a high dependency unit. The nursing staff on the oncology ward have not received an intensive care training but frequently care for acutely ill children. Patients are admitted to the ICU when they require respiratory support, cardiovascular support, or complex monitoring. We have standard policies on our ward for the treatment of febrile neutropenia and for patients presenting with tumour lysis syndrome and airway obstruction.
All febrile neutropenic patients receive early treatment with broad spectrum antibiotics, with haematological support where necessary. If signs of endotoxic shock are present with hypotension, tachycardia, poor peripheral circulation, and reduced urine output then plasma expanders are used. If a rapid response is not obtained inotropic agents are given, initially as low dose dopamine. Providing patients are stable, with restitution of blood pressure, improved circulation, and increased urine output they will continue to be treated on The APACHE-II severity of illness scores, evaluated over the first 24 hours, are shown in the figure. The median score for those who survived was 16 and for those who died was 27. The 95% confidence interval for difference between medians was 7 to 16 (p<0-001). The three patients with APACHE-II scores greater than 30 who survived included a patient with ALL with tumour and metabolic effects; a patient with ALL with acute renal failure and a respiratory infection; and a patient with acute myeloblastic leukaemia (AML) who suffered hypoxia after general anaesthesia.
For all patients, the mean duration of stay in the ICU was 6 days, with a range of 1 to 56 days.
Discussion
This report documents our experience in the use of an intensive care unit by a regional paediatric oncology centre. There are few studies in the literature examining the role of an intensive care unit in this setting. Most are applicable only to adult oncology units, and there is a large variation in results and the conclusions drawn from these studies.2-5 The only similar paediatric report comes from a combined study of three hospitals in Australia and Canada. 6 The overall survival for all children in this study was 51%. The mortality was higher for those children who required ventilation, where there was only a 30% survival. Of those patients not ventilated two subsequently died. For both, an elective decision was made, after admission to the ICU, not to continue with active treatment because of progressive disease. All the remaining patients, who were not ventilated, survived.
The mortality, for patients admitted with a systemic infection, was 84% (16/19). Three patients who did not require ventilation were the only survivors. For those patients with a systemic infection who required ventilation, the mortality was therefore 100%. Febrile neutropenia is a common indication for admission to our oncology ward. We have an aggressive management policy for these patients, and the overall survival is in the order of 98%.' Patients are treated early with broad spectrum antibiotics and receive haematological and cardiovascular support when necessary. The septicaemic patients admitted to the ICU in our study therefore represent those patients where initial intensive therapy had failed and in whom cardiovascular and/or ventilatory support was required.
The majority of febrile neutropenic patients in whom a bacteraemia is diagnosed have a Gram positive infection.7 There were no deaths due to proved Gram positive infections during this period, confirming the low mortality, although high morbidity, associated with these infections. By contrast, Gram negative infections, although fewer in number, remain difficult to control and are associated with a significant mortality.
We are concerned that all ventilated septicaemic patients died. Our experience is similar to that described by Butt et al who also reported a high mortality for these patients. 6 We reviewed in detail the case notes of the septicaemic patients in an attempt to identify factors that may have contributed to the patients' deaths. Factors examined included the time from the onset of marked cardiovascular symptoms to the use of inotropes, the subsequent time to admission to the ICU and to intubation, the indications for intubation, and the time the patient died. There were no common patterns. In four patients a possible factor may have been the delayed use of inotropes which were given more than 24 hours after the onset of marked cardiovascular symptoms, and it is now our practice to use inotropes earlier in the course of the disease. The early use of volume replacement together with low dose dopamine is therefore instituted on the oncology ward in appropriate patients. Admission to the ICU is then considered if the patient's condition remains unstable or if increased inotropic doses or double inotropic agents are required. If the prognosis is to be improved then alternative strategies need to be considered. It is in this group of patients that new therapies such as antiendotoxin antibodies should be evaluated. 8 The best prognosis was seen in those children admitted with metabolic or tumour related effects. Although some of these children had high APACHE-II scores, their short term outlook is good provided their acute complications can be resolved. Patients with non-Hodgkin's lymphoma or acute lymphoblastic leukaemia presenting with a large mediastinal or abdominal mass are at risk for both tumour lysis syndrome and compression of airways or vital organs.
The true extent of airway obstruction may be difficult to assess and may be missed on anteroposterior chest radiographs. A 
